Long-Term Mortality after Recombinant Growth Hormone Treatment for Isolated Growth Hormone Deficiency or Childhood Short Stature: Preliminary Report of the French SAGhE Study | Zendy

JeanClaude Carel | Zendy; Emmanuel Écosse | Zendy; F Landier | Zendy; Djamila Meguellati-Hakkas | Zendy; Florentia Kaguelidou | Zendy; Grégoire Rey | Zendy; Joël Coste | Zendy

Open Access

Long-Term Mortality after Recombinant Growth Hormone Treatment for Isolated Growth Hormone Deficiency or Childhood Short Stature: Preliminary Report of the French SAGhE Study

Author(s) -

JeanClaude Carel,

Emmanuel Écosse,

F Landier,

Djamila Meguellati-Hakkas,

Florentia Kaguelidou,

Grégoire Rey,

Joël Coste

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-1995

Subject(s) - medicine , hazard ratio , pediatrics , short stature , growth hormone deficiency , population , standardized mortality ratio , confidence interval , cohort study , cohort , proportional hazards model , hormone , growth hormone , environmental health

Little is known about the long-term health of subjects treated with GH in childhood, and Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) is a study addressing this question.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research